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Summary
These guidelines have been developed for practitioners who insert catheters and for persons responsible for surveillance and
control of infections in hospital, outpatient, and home health-care settings. This report was prepared by a working group compris-
ing members from professional organizations representing the disciplines of critical care medicine, infectious diseases, health-care
infection control, surgery, anesthesiology, interventional radiology, pulmonary medicine, pediatric medicine, and nursing. The
working group was led by the Society of Critical Care Medicine (SCCM), in collaboration with the Infectious Disease Society of
America (IDSA), Society for Healthcare Epidemiology of America (SHEA), Surgical Infection Society (SIS), American College of
Chest Physicians (ACCP), American Thoracic Society (ATS), American Society of Critical Care Anesthesiologists (ASCCA),
Association for Professionals in Infection Control and Epidemiology (APIC), Infusion Nurses Society (INS), Oncology Nursing
Society (ONS), Society of Cardiovascular and Interventional Radiology (SCVIR), American Academy of Pediatrics (AAP), and
the Healthcare Infection Control Practices Advisory Committee (HICPAC) of the Centers for Disease Control and Prevention
(CDC) and is intended to replace the Guideline for Prevention of Intravascular Device-Related Infections published in 1996.
These guidelines are intended to provide evidence-based recommendations for preventing catheter-related infections. Major areas
of emphasis include 1) educating and training health-care providers who insert and maintain catheters; 2) using maximal sterile
barrier precautions during central venous catheter insertion; 3) using a 2% chlorhexidine preparation for skin antisepsis;
4) avoiding routine replacement of central venous catheters as a strategy to prevent infection; and 5) using antiseptic/antibiotic
impregnated short-term central venous catheters if the rate of infection is high despite adherence to other strategies (i.e., education
and training, maximal sterile barrier precautions, and 2% chlorhexidine for skin antisepsis). These guidelines also identify
performance indicators that can be used locally by health-care institutions or organizations to monitor their success in implement-
ing these evidence-based recommendations.
Introduction
This report provides health-care practitioners with back-
ground information and specific recommendations  to reduce
the incidence of intravascular catheter-related bloodstream
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infections (CRBSI).  These guidelines replace the Guideline
for Prevention of Intravascular Device-Related Infections, which
was published in 1996 (1).
The Guidelines for the Prevention of Intravascular
Catheter-Related Infections have been developed for practitioners
who insert catheters and for persons who are responsible for
surveillance and control of infections in hospital, outpatient,
and home health-care settings. This report was prepared by a
working group composed of professionals representing the
disciplines of critical care medicine, infectious diseases,
health-care infection control, surgery, anesthesiology,
interventional radiology, pulmonary medicine, pediatrics, and
nursing. The working group was led by the Society of Critical
Care Medicine (SCCM), in collaboration with Infectious
Disease Society of America (IDSA), Society for Healthcare
Epidemiology of America (SHEA), Surgical Infection Society
(SIS), American College of Chest Physicians (ACCP), Ameri-
can Thoracic Society (ATS), American Society of Critical Care
Anesthesiologists (ASCCA), Association for Professionals in
Infection Control and Epidemiology (APIC), Infusion Nurses
Society (INS), Oncology Nursing Society (ONS), Society of
Cardiovascular and Interventional Radiology (SCVIR), Ameri-
can Academy of Pediatrics (AAP), and the Healthcare Infec-
tion Control Practices Advisory Committee (HICPAC) of the
Centers for Disease Control and Prevention (CDC). The rec-
ommendations presented in this report reflect consensus of
HICPAC and other professional organizations.
Intravascular Catheter-Related
Infections in Adult and Pediatric
Patients: An Overview
Background
Intravascular catheters are indispensable in modern-day
medical practice, particularly in intensive care units (ICUs).
Although such catheters provide necessary vascular access, their
use puts patients at risk for local and systemic infectious com-
plications, including local site infection, CRBSI, septic throm-
bophlebitis, endocarditis, and other metastatic infections (e.g.,
lung abscess, brain abscess, osteomyelitis, and endophthalmitis).
Health-care institutions purchase millions of intravascular
catheters each year. The incidence of CRBSI varies consider-
ably by type of catheter, frequency of catheter manipulation,
and patient-related factors (e.g., underlying disease and acuity
of illness). Peripheral venous catheters are the devices most
frequently used for vascular access. Although the incidence of
local or bloodstream infections (BSIs) associated with periph-
eral venous catheters is usually low, serious infectious compli-
cations produce considerable annual morbidity because of the
frequency with which such catheters are used. However, the
majority of serious catheter-related infections are associated
with central venous catheters (CVCs), especially those that
are placed in patients in ICUs. In the ICU setting, the inci-
dence of infection is often higher than in the less acute
in-patient or ambulatory setting. In the ICU, central venous
access might be needed for extended periods of time; patients
can be colonized with hospital-acquired organisms; and the
catheter can be manipulated multiple times per day for the
administration of fluids, drugs, and blood products. More-
over, some catheters can be inserted in urgent situations, dur-
ing which optimal attention to aseptic technique might not
be feasible. Certain catheters (e.g., pulmonary artery catheters
and peripheral arterial catheters) can be accessed multiple times
per day for hemodynamic measurements or to obtain samples
for laboratory analysis, augmenting the potential for contami-
nation and subsequent clinical infection.
The magnitude of the potential for CVCs to cause morbid-
ity and mortality resulting from infectious complications
has been estimated in several studies (2). In the United States,
15 million CVC days (i.e., the total number of days of expo-
sure to CVCs by all patients in the selected population during
the selected time period) occur in ICUs each year (2). If the
average rate of CVC-associated BSIs is 5.3 per 1,000 catheter
days in the ICU (3), approximately 80,000 CVC-associated
BSIs occur in ICUs each year in the United States. The attrib-
utable mortality for these BSIs has ranged from no increase in
mortality in studies that controlled for severity of illness
(4–6), to 35% increase in mortality in prospective studies that
did not use this control (7,8). Thus, the attributable mortality
remains unclear. The attributable cost per infection is an esti-
mated $34,508–$56,000 (5,9), and the annual cost of caring
for patients with CVC-associated BSIs ranges from $296 mil-
lion to $2.3 billion (10).
A total of 250,000 cases of CVC-associated BSIs have been
estimated to occur annually if entire hospitals are assessed rather
than ICUs exclusively (11). In this case, attributable mortality
is an estimated 12%–25% for each infection, and the marginal
cost to the health-care system is $25,000 per episode (11).
 Therefore, by several analyses, the cost of CVC-associated
BSI is substantial, both in terms of morbidity and in terms of
financial resources expended. To improve patient outcome and
reduce health-care costs, strategies should be implemented to
reduce the incidence of these infections. This effort should be
multidisciplinary, involving health-care professionals who
insert and maintain intravascular catheters, health-care man-
agers who allocate resources, and patients who are capable of
assisting in the care of their catheters. Although several indi-
vidual strategies have been studied and shown to be effective
in reducing CRBSI, studies using multiple strategies have not
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been conducted. Thus, it is not known whether implementing
multiple strategies will have an additive effect in reducing CRBSI,
but it is logical to use multiple strategies concomitantly.
Terminology and Estimates of Risk
The terminology used to identify different types of cath-
eters is confusing, because many clinicians and researchers use
different aspects of the catheter for informal reference. A
catheter can be designated by the type of vessel it occupies
(e.g., peripheral venous, central venous, or arterial); its intended
life span (e.g., temporary or short-term versus permanent or
long-term); its site of insertion (e.g., subclavian, femoral,
internal jugular, peripheral, and peripherally inserted central
catheter [PICC]); its pathway from skin to vessel (e.g., tun-
neled versus nontunneled); its physical length (e.g., long ver-
sus short); or some special characteristic of the catheter (e.g.,
presence or absence of a cuff, impregnation with heparin,
antibiotics or antiseptics, and the number of lumens). To
accurately define a specific type of catheter, all of these aspects
should be described (Table 1).
The rate of all catheter-related infections (including local
infections and systemic infections) is difficult to determine.
Although CRBSI is an ideal parameter because it represents
the most serious form of catheter-related infection, the rate of
such infection depends on how CRBSI is defined.
Health-care professionals should recognize the difference
between surveillance definitions and clinical definitions. The
surveillance definitions for catheter-associated BSI includes
all BSIs that occur in patients with CVCs, when other sites of
infection have been excluded (Appendix A). That is, the sur-
veillance definition overestimates the true incidence of CRBSI
because not all BSIs originate from a catheter. Some bacteremias
are secondary BSIs from undocumented sources (e.g.,
postoperative surgical sites, intra-abdominal infections, and
hospital-associated pneumonia or urinary tract infections).
Thus, surveillance definitions are really definitions for
Peripheral venous catheters
(short)
Peripheral arterial catheters
Midline catheters
Nontunneled central venous
catheters
Pulmonary artery catheters
Peripherally inserted central
venous catheters (PICC)
Tunneled central venous catheters
Totally implantable
Umbilical catheters
Usually inserted in veins of
forearm or hand
Usually inserted in radial artery;
can be placed in femoral, axillary,
brachial, posterior tibial arteries
Inserted via the antecubital fossa
into the proximal basilic or
cephalic veins; does not enter
central veins, peripheral catheters
Percutaneously inserted into
central veins (subclavian, internal
jugular, or femoral)
Inserted through a Teflon®
introducer in a central vein
(subclavian, internal jugular, or
femoral)
Inserted into basilic, cephalic, or
brachial veins and enter the
superior vena cava
Implanted into subclavian, internal
jugular, or femoral veins
Tunneled beneath skin and have
subcutaneous port accessed with
a needle; implanted in subclavian
or internal jugular vein
Inserted into either umbilical vein
or umbilical artery
<3 inches; rarely associated with
bloodstream infection
<3 inches; associated with
bloodstream infection
3 to 8 inches
>8 cm depending on patient size
>30 cm depending on patient size
>20 cm depending on patient size
>8 cm depending on patient size
>8 cm depending on patient size
<6 cm depending on patient size
Phlebitis with prolonged use;
rarely associated with bloodstream
infection
Low infection risk; rarely associ-
ated with bloodstream infection
Anaphylactoid reactions have
been reported with catheters
made of elastomeric hydrogel;
lower rates of phlebitis than short
peripheral catheters
Account for majority of CRBSI
Usually heparin bonded; similar
rates of bloodstream infection as
CVCs; subclavian site preferred to
reduce infection risk
Lower rate of infection than
nontunneled CVCs
Cuff inhibits migration of organ-
isms into catheter tract; lower rate
of infection than nontunneled CVC
Lowest risk for CRBSI; improved
patient self-image; no need for
local catheter-site care; surgery
required for catheter removal
Risk for CRBSI similar with
catheters placed in umbilical vein
versus artery
TABLE 1. Catheters used for venous and arterial access
Catheter type Entry site Length Comments
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TABLE 2. Pooled means of the distribution of central venous
catheter-associated bloodstream infection rates in hospitals
reporting to the National Nosocomial Infection Surveillance
System, January 1992–June 2001 (issued August 2001)
Pool
Type of Catheter mean/1,000
intensive care unit No. days catheter-days
Coronary 102 252,325 4.5
Cardiothoracic 64 419,674 2.9
Medical 135 671,632 5.9
Medical/surgical
Major teaching 123 579,704 5.3
All others 180 863,757 3.8
Neurosurgical 47 123,780 4.7
Nursery, high risk (HRN)
<1,000 g 138 438,261 11.3
1,001–1,500 g 136 213,351 6.9
1,501–2,500 g 132 163,697 4.0
>2,500 g 133 231,573 3.8
Pediatric 74 291,831 7.6
Surgical 153 900,948 5.3
Trauma 25 116,709 7.9
Burn 18 43,196 9.7
Respiratory 7 21,265 3.4
TABLE 3. Most common pathogens isolated from hospital
acquired bloodstream infections
1986–1989 1992–1999
Pathogen (%) (%)
Coagulase-negative staphylococci 27 37
Staphylococcus aureus 16 13
Enterococcus 8 13
Gram-negative rods 19 14
Escherichia coli 6 2
Enterobacter 5 5
Pseudomonas aeruginosa 4 4
Klebsiella pneumoniae 4 3
Candida spp. 8 8
catheter-associated BSIs. A more rigorous definition might
include only those BSIs for which other sources were excluded
by careful examination of the patient record, and where a
culture of the catheter tip demonstrated substantial colonies
of an organism identical to those found in the bloodstream.
Such a clinical definition would focus on catheter-related BSIs.
Therefore, to accurately compare a health-care facility’s infection
rate to published data, comparable definitions also should be used.
CDC and the Joint Commission on Accreditation of
Healthcare Organizations (JCAHO) recommend that the rate
of catheter-associated BSIs be expressed as the number of cath-
eter associated BSIs per 1,000 CVC days (12,13). This
parameter is more useful than the rate expressed as the num-
ber of catheter-associated infections per 100 catheters (or per-
centage of catheters studied), because it accounts for BSIs over
time and therefore adjusts risk for the number of days the
catheter is in use.
Epidemiology and Microbiology
Since 1970, CDC’s National Nosocomial Infection Surveil-
lance System (NNIS) has been collecting data on the inci-
dence and etiologies of hospital-acquired infections, including
CVC-associated BSIs in a group of nearly 300 U.S. hospitals.
The majority of hospital-acquired BSIs are associated with the
use of a CVC, with BSI rates being substantially higher among
patients with CVCs than among those without CVCs. Rates
of CVC-associated BSI vary considerably by hospital size, hos-
pital service/unit, and type of CVC. During 1992–2001, NNIS
hospitals reported ICU rates of CVC-associated BSI ranging
from 2.9 (in a cardiothoracic ICU) to 11.3 (in a neonatal nurs-
ery for infants weighing <1,000 g) BSIs per 1,000 CVC days
(Table 2) (14).
The relative risk of catheter-associated BSI also has been
assessed in a meta-analysis of 223 prospective studies of adult
patients (11). Relative risk of infection was best determined
by analyzing rates of infection both by BSIs per 100 catheters
and BSIs per 1,000 catheter days. These rates, and the NNIS-
derived data, can be used as benchmarks by individual hospi-
tals to estimate how their rates compare with other institutions.
Rates are influenced by patient-related parameters, such as
severity of illness and type of illness (e.g., third-degree burns
versus postcardiac surgery), and by catheter-related parameters,
such as the condition under which the catheter was placed
(e.g., elective versus urgent) and catheter type (e.g., tunneled
versus nontunneled or subclavian versus jugular).
Types of organisms that most commonly cause hospital-
acquired BSIs change over time. During 1986–1989, coagulase-
negative staphylococci, followed by Staphylococcus aureus, were
the most frequently reported causes of BSIs, accounting for
27% and 16% of BSIs, respectively (Table 3) (15). Pooled
data from 1992 through 1999 indicate that coagulase-
negative staphylococci, followed by enterococci, are now the
most frequently isolated causes of hospital-acquired BSIs (12).
Coagulase-negative staphylococci account for 37% (12) and
S. aureus account for 12.6% of reported hospital-acquired BSIs
(12). Also notable was the susceptibility pattern of S. aureus
isolates. In 1999, for the first time since NNIS has been
reporting susceptibilities, >50% of all S. aureus isolates from
ICUs were resistant to oxacillin (12).
In 1999, enterococci accounted for 13.5% of BSIs, an
increase from 8% reported to NNIS during 1986–1989. The
percentage of enterococcal ICU isolates resistant to vancomy-
cin also is increasing, escalating from 0.5% in 1989 to 25.9%
in 1999 (12).
Candida spp. caused 8% of hospital-acquired BSIs reported
to NNIS during 1986–1989 (15,16), and during 1992–1999
(12,17,18). Resistance of Candida spp. to commonly used
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antifungal agents is increasing. Although NNIS has not
reported the percentage of BSIs caused by nonalbicans species
or fluconazole susceptibility data, other epidemiologic and
clinical data document that fluconazole resistance is an
increasingly relevant consideration when designing empiric
therapeutic regimens for CRBSIs caused by yeast. Data from
the Surveillance and Control of Pathogens of Epidemiologic
Importance (SCOPE) Program documented that 10% of
C. albicans bloodstream isolates from hospitalized patients were
resistant to fluconazole (17). Additionally, 48% of Candida
BSIs were caused by nonalbicans species, including C. glabrata
and C. krusei, which are more likely than C. albicans to dem-
onstrate resistance to fluconazole and itraconazole (18,19).
Gram-negative bacilli accounted for 19% of catheter-
associated BSIs during 1986–1989 (15) compared with 14%
of catheter-associated BSIs during 1992–1999 (12). An
increasing percentage of ICU-related isolates are caused by
Enterobacteriaceae that produce extended-spectrum
ß-lactamases (ESBLs), particularly Klebsiella pneumoniae (20).
Such organisms not only are resistant to extended-spectrum
cephalosporins, but also to frequently used, broad spectrum
antimicrobial agents.
Pathogenesis
Migration of skin organisms at the insertion site into the
cutaneous catheter tract with colonization of the catheter tip
is the most common route of infection for peripherally
inserted, short-term catheters (21,22). Contamination of the
catheter hub contributes substantially to intraluminal coloni-
zation of long-term catheters (23–25). Occasionally, catheters
might become hematogenously seeded from another focus of
infection. Rarely, infusate contamination leads to CRBSI (26).
Important pathogenic determinants of catheter-related
infection are 1) the material of which the device is made and
2) the intrinsic virulence factors of the infecting organism. In
vitro studies demonstrate that catheters made of polyvinyl
chloride or polyethylene are likely less resistant to the adher-
ence of microorganisms than are catheters made of Teflon®,
silicone elastomer, or polyurethane (27,28). Therefore, the
majority of catheters sold in the United States are no longer
made of polyvinyl chloride or polyethylene. Some catheter
materials also have surface irregularities that enhance the mi-
crobial adherence of certain species (e.g., coagulase-negative
staphylococci, Acinetobacter calcoaceticus, and Pseudomonas
aeruginosa) (29–31); catheters made of these materials are
especially vulnerable to microbial colonization and subsequent
infection. Additionally, certain catheter materials are more
thrombogenic than others, a characteristic that also might
predispose to catheter colonization and catheter-related
infection (31,32). This association has led to emphasis on pre-
venting catheter-related thrombus as an additional mechanism
for reducing CRBSI.
The adherence properties of a given microorganism also are
important in the pathogenesis of catheter-related infection.
For example, S. aureus can adhere to host proteins (e.g.,
fibronectin) commonly present on catheters (33,34). Also,
coagulase-negative staphylococci adhere to polymer surfaces
more readily than do other pathogens (e.g., Escherichia coli or
S. aureus). Additionally, certain strains of coagulase-negative
staphylococci produce an extracellular polysaccharide often
referred to as “slime” (35,36). In the presence of catheters,
this slime potentiates the pathogenicity of coagulase-negative
staphylococci by allowing them to withstand host defense
mechanisms (e.g., acting as a barrier to engulfment and kill-
ing by polymorphonuclear leukocytes) or by making them less
susceptible to antimicrobial agents (e.g., forming a matrix that
binds antimicrobials before their contact with the organism
cell wall) (37). Certain Candida spp., in the presence of
glucose-containing fluids, might produce slime similar to that
of their bacterial counterparts, potentially explaining the
increased proportion of BSIs caused by fungal pathogens
among patients receiving parenteral nutrition fluids (38).
Strategies for Prevention
of Catheter-Related Infections
in Adult and Pediatric Patients
Quality Assurance and Continuing
Education
Measures to minimize the risk for infection associated with
intravascular therapy should strike a balance between patient
safety and cost effectiveness. As knowledge, technology, and
health-care settings change, infection control and prevention
measures also should change. Well-organized programs that
enable health-care providers to provide, monitor, and evaluate
care and to become educated are critical to the success of this
effort. Reports spanning the past two decades have consis-
tently demonstrated that risk for infection declines following
standardization of aseptic care (39–43), and that insertion and
maintenance of intravascular catheters by inexperienced staff
might increase the risk for catheter colonization and CRBSI
(43,44). Specialized “IV teams” have shown unequivocal ef-
fectiveness in reducing the incidence of catheter-related infec-
tions and associated complications and costs (45–47).
Additionally, infection risk increases with nursing staff reduc-
tions below a critical level (48).
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Site of Catheter Insertion
The site at which a catheter is placed influences the subse-
quent risk for catheter-related infection and phlebitis. The
influence of site on the risk for catheter infections is related in
part to the risk for thrombophlebitis and density of local skin flora.
Phlebitis has long been recognized as a risk for infection.
For adults, lower extremity insertion sites are associated with
a higher risk for infection than are upper extremity sites
(49–51). In addition, hand veins have a lower risk for phlebi-
tis than do veins on the wrist or upper arm (52).
The density of skin flora at the catheter insertion site is a
major risk factor for CRBSI. Authorities recommend that
CVCs be placed in a subclavian site instead of a jugular or
femoral site to reduce the risk for infection. No randomized
trial satisfactorily has compared infection rates for catheters
placed in jugular, subclavian, and femoral sites. Catheters in-
serted into an internal jugular vein have been
associated with higher risk for infection than those inserted
into a subclavian or femoral vein (22,53,54).
Femoral catheters have been demonstrated to have relatively
high colonization rates when used in adults (55). Femoral cath-
eters should be avoided, when possible, because they are asso-
ciated with a higher risk for deep venous thrombosis than are
internal jugular or subclavian catheters (56–60) and because
of a presumption that such catheters are more likely to
become infected. However, studies in pediatric patients have
demonstrated that femoral catheters have a low incidence of
mechanical complications and might have an equivalent
infection rate to that of nonfemoral catheters (61–63). Thus,
in adult patients, a subclavian site is preferred for infection
control purposes, although other factors (e.g., the potential
for mechanical complications, risk for subclavian vein steno-
sis, and catheter-operator skill) should be considered when
deciding where to place the catheter. In a meta-analysis of eight
studies, the use of bedside ultrasound for the placement
of CVCs substantially reduced mechanical complications
compared with the standard landmark placement technique
(relative risk [RR] = 0.22; 95% confidence interval
[CI] = 0.10–0.45) (64). Consideration of comfort, security,
and maintenance of asepsis as well as patient-specific factors
(e.g., preexisting catheters, anatomic deformity, and bleeding
diathesis), relative risk of mechanical complications (e.g., bleed-
ing and pneumothorax), the availability of bedside ultrasound,
and the risk for infection should guide site selection.
Type of Catheter Material
Teflon® or polyurethane catheters have been associated with
fewer infectious complications than catheters made of polyvinyl
chloride or polyethylene (27,65,66). Steel needles used as an
alternative to catheters for peripheral venous access have the
same rate of infectious complications as do Teflon® catheters
(67,68). However, the use of steel needles frequently is
complicated by infiltration of intravenous (IV) fluids into the
subcutaneous tissues, a potentially serious complication if the
infused fluid is a vesicant (68).
Hand Hygiene and Aseptic Technique
For short peripheral catheters, good hand hygiene before
catheter insertion or maintenance, combined with proper asep-
tic technique during catheter manipulation, provides protec-
tion against infection. Good hand hygiene can be achieved
through the use of either a waterless, alcohol-based product
(69) or an antibacterial soap and water with adequate rinsing
(70). Appropriate aseptic technique does not necessarily
require sterile gloves; a new pair of disposable nonsterile gloves
can be used in conjunction with a “no-touch” technique for
the insertion of peripheral venous catheters. However, gloves
are required by the Occupational Safety and Health Adminis-
tration as standard precautions for the prevention of
bloodborne pathogen exposure.
Compared with peripheral venous catheters, CVCs carry a
substantially greater risk for infection; therefore, the level of
barrier precautions needed to prevent infection during inser-
tion of CVCs should be more stringent. Maximal sterile bar-
rier precautions (e.g., cap, mask, sterile gown, sterile gloves,
and large sterile drape) during the insertion of CVCs substan-
tially reduces the incidence of CRBSI compared with stan-
dard precautions (e.g., sterile gloves and small drapes) (22,71).
Although the efficacy of such precautions for insertion of
PICCs and midline catheters has not been studied, the use of
maximal barrier precautions also is probably applicable to
PICCs.
Skin Antisepsis
In the United States, povidone iodine has been the most
widely used antiseptic for cleansing arterial catheter and CVC-
insertion sites (72). However, in one study, preparation of cen-
tral venous and arterial sites with a 2% aqueous chlorhexidine
gluconate lowered BSI rates compared with site preparation
with 10% povidone-iodine or 70% alcohol (73). Commer-
cially available products containing chlorhexidine have not
been available until recently; in July 2000, the U.S. Food and
Drug Administration (FDA) approved a 2% tincture of
chlorhexidine preparation for skin antisepsis. Other prepara-
tions of chlorhexidine might not be as effective. Tincture of
chlorhexidine gluconate 0.5% is no more effective in prevent-
ing CRBSI or CVC colonization than 10% povidone iodine,
as demonstrated by a prospective, randomized study of adults
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(74). However, in a study involving neonates, 0.5%
chlorhexidine reduced peripheral IV colonization compared
with povidone iodine (20/418 versus 38/408 catheters;
p = 0.01) (75). This study, which did not include CVCs, had
an insufficient number of participants to assess differences in
BSI rates. A 1% tincture of chlorhexidine preparation is avail-
able in Canada and Australia, but not yet in the United States.
No published trials have compared a 1% chlorhexidine prepara-
tion to povidone-iodine.
Catheter Site Dressing Regimens
Transparent, semipermeable polyurethane dressings have
become a popular means of dressing catheter insertion sites.
Transparent dressings reliably secure the device, permit con-
tinuous visual inspection of the catheter site, permit patients
to bathe and shower without saturating the dressing, and
require less frequent changes than do standard gauze and tape
dressings; the use of these dressings saves personnel time.
In the largest controlled trial of dressing regimens on
peripheral catheters, the infectious morbidity associated with
the use of transparent dressings on approximately 2,000
peripheral catheters was examined (65). Data from this study
suggest that the rate of colonization among catheters dressed
with transparent dressings (5.7%) is comparable to that of
those dressed with gauze (4.6%) and that no clinically sub-
stantial differences exist in either the incidences of catheter-
site colonization or phlebitis. Furthermore, these data suggest
that transparent dressings can be safely left on peripheral venous
catheters for the duration of catheter insertion without
increasing the risk for thrombophlebitis (65).
A meta-analysis has assessed studies that compared the risk
for catheter-related BSIs for groups using transparent dress-
ings versus groups using gauze dressing (76). The risk for
CRBSIs did not differ between the groups. The choice of dress-
ing can be a matter of preference. If blood is oozing from the
catheter insertion site, gauze dressing might be preferred.
In a multi-center study, a chlorhexidine-impregnated sponge
(Biopatch™) placed over the site of short-term arterial and
CVCs reduced the risk for catheter colonization and CRBSI
(77). No adverse systemic effects resulted from use of this
device.
Catheter Securement Devices
Sutureless securement devices can be advantageous over
suture in preventing catheter-related BSIs. One study, which
involved only a limited number of patients and was under-
powered, compared a sutureless device with suture for the
securement of PICCS; in this study, CRBSI was reduced in
the group of patients that received the sutureless device (78).
In-Line Filters
In-line filters reduce the incidence of infusion-related phle-
bitis (79,80). No data support their efficacy in preventing
infections associated with intravascular catheters and infusion
systems. Proponents of filters cite several potential benefits to
using these filters, including 1) reducing the risk for infection
from contaminated infusate or proximal contamination (i.e.,
introduced proximal to the filter); 2) reducing the risk for
phlebitis in patients who require high doses of medication or
in those in whom infusion-related phlebitis already has
occurred; 3) removing particulate matter that might contami-
nate IV fluids (81); and 4) filtering endotoxin produced by
gram-negative organisms in contaminated infusate (82). These
theoretical advantages should be tempered by the knowledge
that infusate-related BSI is rare and that filtration of medica-
tions or infusates in the pharmacy is a more practical and less
costly way to remove the majority of particulates. Further-
more, in-line filters might become blocked, especially with
certain solutions (e.g., dextran, lipids, and mannitol), thereby
increasing the number of line manipulations and decreasing
the availability of administered drugs (83). Thus, for reduc-
ing the risk for CRBSI, no strong recommendation can be
made in favor of using in-line filters.
Antimicrobial/Antiseptic Impregnated
Catheters and Cuffs
Certain catheters and cuffs that are coated or impregnated
with antimicrobial or antiseptic agents can decrease the risk
for CRBSI and potentially decrease hospital costs associated
with treating CRBSIs, despite the additional acquisition cost
of an antimicrobial/antiseptic impregnated catheter (84). All
of the studies involving antimicrobial/antiseptic impregnated
catheters have been conducted using triple-lumen, noncuffed
catheters in adult patients whose catheters remained in place
<30 days. Although all of the studies have been conducted in
adults, these catheters have been approved by FDA for use in
patients weighing >3 kg. No antiseptic or antimicrobial
impregnated catheters currently are available for use in
weighing <3 kg.
Chlorhexidine/Silver sulfadiazine. Catheters coated with
chlorhexidine/silver sulfadiazine only on the external luminal
surface have been studied as a means to reduce CRBSI. Two
meta-analyses (2,85) demonstrated that such catheters reduced
the risk for CRBSI compared with standard noncoated
catheters. The mean duration of catheter placement in one
meta-analysis ranged from 5.1 to 11.2 days (86). The half-life
of antimicrobial activity against S. epidermidis is 3 days in vitro
for catheters coated with chlorhexidine/silver sulfadiazine; this
antimicrobial activity decreases over time (87). The benefit
8 MMWR August 9, 2002
for the patients who receive these catheters will be realized
within the first 14 days (86). A second-generation catheter is
now available with chlorhexidine coating both the internal
and external luminal surfaces. The external surface has three
times the amount of chlorhexidine and extended release of
the surface bound antiseptics than that in the first generation
catheters. The external surface coating of chlorhexidine is com-
bined with silver-sulfadiazine, and the internal surface is coated
with chlorhexidine alone. Preliminary studies indicate that
prolonged anti-infective activity provides improved efficacy
in preventing infections (88). Although rare, anaphylaxis has
been reported with the use of these chlorhexidine/silver sulfa-
diazine catheters in Japan (89). Whether patients will become
colonized or infected with organisms resistant to chlorhexidine/
silver sulfadiazine has not been determined (86).
 Chlorhexidine/silver sulfadiazine catheters are more expen-
sive than standard catheters. However, one analysis has sug-
gested that the use of chlorhexidine/silver sulfadiazine catheters
should lead to a cost savings of $68 to $391 per catheter (90)
in settings in which the risk for CRBSI is high despite adher-
ence to other preventive strategies (e.g., maximal barrier pre-
cautions and aseptic techniques). Use of these catheters might
be cost effective in ICU patients, burn patients, neutropenic
patients, and other patient populations in which the rate of
infection exceeds 3.3 per 1,000 catheter days (86).
Minocycline/Rifampin. In a multicenter randomized trial,
CVCs impregnated on both the external and internal surfaces
with minocycline/rifampin were associated with lower rates
of CRBSI when compared with the first-generation
chlorhexidine-silver sulfadiazine impregnated catheters (91).
The beneficial effect began after day 6 of catheterization. None
of the catheters were evaluated beyond 30 days. No
minocycline/rifampin-resistant organisms were reported. How-
ever, in vitro data indicate that these impregnated catheters
could increase the incidence of minocycline and rifampin
resistance among pathogens, especially staphylococci. The half-
life of antimicrobial activity against S. epidermidis is 25 days
with catheters coated with minocycline/rifampin, compared
with 3 days for the first-generation catheters coated with
chlorhexidine/silver sulfadiazine in vitro (87). In vivo, the
duration of antimicrobial activity of the minocycline/rifampin
catheter is longer than that of the first-generation chlorhexidine/
silver sulfadiazine catheter (91). No comparative studies have
been published using the second-generation chlorhexidine/
silver sulfadiazine catheter. Studies are needed to evaluated
whether the improved performance of the minocyline/rifampin
catheters results from the antimicrobial agents used or from
the coating of both the internal and external surfaces. As with
chlorhexidine/silver sulfadiazine catheters, some clinicians have
recommended that the minocycline/rifampin catheters be
considered in patient populations when the rate of CRBSI
exceeds 3.3 per 1,000 catheter days (86). Others suggest that
reducing all rates of CRBSI should be the goal (92). The deci-
sion to use chlorhexidine/silver sulfadiazine or minocycline/
rifampin impregnated catheters should be based on the need
to enhance prevention of CRBSI after standard procedures
have been implemented (e.g., educating personnel, using maxi-
mal sterile barrier precautions, and using 2% chlorhexidine
skin antisepsis) and then balanced against the concern for
emergence of resistant pathogens and the cost of implementing
this strategy.
Platinum/Silver. Ionic metals have broad antimicrobial
activity and are being used in catheters and cuffs to prevent
CRBSI. A combination platinum/silver impregnated catheter
is available in Europe and has recently been approved by FDA
for use in the United States. Although these catheters are
being marketed for their antimicrobial properties, no published
studies have been presented to support an antimicrobial effect.
Silver cuffs. Ionic silver has been used in subcutaneous col-
lagen cuffs attached to CVCs (93). The ionic silver provides
antimicrobial activity and the cuff provides a mechanical bar-
rier to the migration of microorganisms along the external
surface of the catheter. In studies of catheters left in place >20
days, the cuff failed to reduce the incidence of CRBSI (94,95).
Two other studies of short-term catheters could not demon-
strate efficacy because of the minimal number of CRBSIs
observed (93,96).
Systemic Antibiotic Prophylaxis
No studies have demonstrated that oral or parenteral anti-
bacterial or antifungal drugs might reduce the incidence of
CRBSI among adults (97–99). However, among low birth
weight infants, two studies have assessed vancomycin prophy-
laxis; both demonstrated a reduction in CRBSI but no reduc-
tion in mortality (100,101). Because the prophylactic use of
vancomycin is an independent risk factor for the acquisition
of vancomycin-resistant enterococcus (VRE) (102), the risk
for acquiring VRE likely outweighs the benefit of using pro-
phylactic vancomycin.
Antibiotic/Antiseptic Ointments
Povidone-iodine ointment applied at the insertion site of
hemodialysis catheters has been studied as a prophylactic
intervention to reduce the incidence of catheter-related
infections. One randomized study of 129 hemodialysis cath-
eters demonstrated a reduction in the incidence of exit-site
infections, catheter-tip colonization, and BSIs with the rou-
tine use of povidone-iodine ointment at the catheter insertion
site compared with no ointment at the insertion site (103).
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Several studies have evaluated the effectiveness of mupirocin
ointment applied at the insertion sites of CVCs as a means to
prevent CRBSI (104–106). Although mupirocin reduced the
risk for CRBSI (106), mupirocin ointment also has been asso-
ciated with mupirocin resistance (107,108), and might adversely
affect the integrity of polyurethane catheters (109,110).
Nasal carriers of S. aureus have a higher risk for acquiring
CRBSI than do noncarriers (103,111). Mupirocin ointment
has been used intranasally to decrease nasal carriage of S. aureus
and lessen the risk for CRBSI. However, resistance to
mupirocin develops in both S. aureus and coagulase-negative
staphylococci soon after routine use of mupirocin is instituted
(107,108).
Other antibiotic ointments applied to the catheter inser-
tion site also have been studied and have yielded conflicting
results (112–114). In addition, rates of catheter colonization
with Candida spp. might be increased with the use of antibi-
otic ointments that have no fungicidal activity (112,114). To
avoid compromising the integrity of the catheter, any oint-
ment that is applied to the catheter insertion site should be
checked against the catheter and ointment manufacturers’ rec-
ommendations regarding compatibility.
Antibiotic Lock Prophylaxis
To prevent CRBSI, antibiotic lock prophylaxis has been
attempted by flushing and filling the lumen of the catheter
with an antibiotic solution and leaving the solution to dwell
in the lumen of the catheter. Three studies have demonstrated
the usefulness of such prophylaxis in neutropenic patients with
long-term catheters (115–117). In two of the studies, patients
received either heparin alone (10 U/ml) or heparin plus 25
micrograms/ml of vancomycin. The third study compared
vancomycin/ciprofloxacin/heparin (VCH) to vancomycin/
heparin (VH)and then to heparin alone. The rate of CRBSI
with vancomycin-susceptible organisms was significantly lower
(VCH p = 0.022; VH p = 0.028) and the time to the first
episode of bacteremia with vancomycin-susceptible organisms
was substantially longer (VCH p = 0.036; VH p = 0.011) in
patients receiving either vancomycin/ciprofloxacin/heparin or
vancomycin/heparin compared with heparin alone (115–117).
One study involving a limited number of children revealed no
difference in rates of CRBSI between children receiving a
heparin flush compared with those receiving heparin and van-
comycin (118). However, because the use of vancomycin is an
independent risk factor for the acquisition of VRE (102), this
practice is not recommended routinely.
An anticoagulant/antimicrobial combination comprising
minocycline and ethylenediaminetetraraacetic acid (EDTA)
has been proposed as a lock solution because it has antibiofilm
and antimicrobial activity against gram-positive, gram-
negative, and Candida organisms (119), as well as anticoagu-
lant properties. However, no controlled or randomized trials
have demonstrated its efficacy.
Anticoagulants
Anticoagulant flush solutions are used widely to prevent cath-
eter thrombosis. Because thrombi and fibrin deposits on cath-
eters might serve as a nidus for microbial colonization of
intravascular catheters (120,121), the use of anticoagulants
might have a role in the prevention of CRBSI.
In a meta-analysis evaluating the benefit of heparin prophy-
laxis (3 U/ml in TPN, 5,000 U every 6 or 12 hours flush, or
2,500 U low molecular weight heparin subcutaneously) in
patients with short-term CVCs, the risk for catheter-related
central venous thrombosis was reduced with the use of pro-
phylactic heparin (122). However, no substantial difference
in the rate for CRBSI was observed. Because the majority of
heparin solutions contain preservatives with antimicrobial
activity, whether any decrease in the rate of CRBSI is a result
of the reduced thrombus formation, the preservative, or both
is unclear.
The majority of pulmonary artery, umbilical, and central
venous catheters are available with a heparin-bonded coating.
The majority are heparin-bonded with benzalkonium chlo-
ride, which provides the catheters with antimicrobial activity
(123) and provides an anti-thrombotic effect (124).
Warfarin also has been evaluated as a means for reducing
CRBSI by reducing thrombus formation on catheters
(125,126). In patients with long-term CVCs, low-dose war-
farin (i.e., 1 mg/day) reduced the incidence of catheter throm-
bus. No data demonstrate that warfarin reduces the incidence
of CRBSI.
Replacement of Catheters
Peripheral Venous Catheters
Scheduled replacement of intravascular catheters has been
proposed as a method to prevent phlebitis and catheter-
related infections. Studies of short peripheral venous catheters
indicate that the incidence of thrombophlebitis and bacterial
colonization of catheters increases when catheters are left in
place >72 hours (66,67,127). However, rates of phlebitis are
not substantially different in peripheral catheters left in place
72 hours compared with 96 hours (128). Because phlebitis
and catheter colonization have been associated with an
increased risk for catheter-related infection, short peripheral
catheter sites commonly are rotated at 72–96-hour intervals
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to reduce both the risk for infection and patient discomfort
associated with phlebitis.
Midline Catheters
Midline catheters have been associated with lower rates of
phlebitis than short peripheral catheters and with lower rates
of infection than CVCs (129–131). In one prospective study
of 140 midline catheters, their use was associated with a BSI
rate of 0.8 per 1,000 catheter-days (131). No specific risk fac-
tors, including duration of catheterization, were associated with
infection. Midline catheters were in place a median of 7 days,
but for as long as 49 days. Although the findings of this study
suggested that midline catheters can be changed only when
there is a specific indication, no prospective, randomized stud-
ies have assessed the benefit of routine replacement as a strat-
egy to prevent CRBSI associated with midline catheters.
CVCs, Including PICCs and
Hemodialysis Catheters
Catheter replacement at scheduled time intervals as a method
to reduce CRBSI has not lowered rates. Two trials have
assessed a strategy of changing the catheter every 7 days com-
pared with a strategy of changing catheters as needed (132,133).
One of these studies involved 112 surgical ICU patients need-
ing CVCs, pulmonary artery catheters, or peripheral arterial
catheters (132), whereas the other study involved only subcla-
vian hemodialysis catheters (133). In both studies, no differ-
ence in CRBSI was observed in patients undergoing scheduled
catheter replacement every 7 days compared with patients
whose catheters were replaced as needed.
Scheduled guidewire exchanges of CVCs is another proposed
strategy for preventing CRBSI. The results of a meta-analysis
of 12 randomized controlled trials assessing CVC manage-
ment failed to prove any reduction of CRBSI rates through
routine replacement of CVCs by guidewire exchange com-
pared with catheter replacement on an as-needed basis (134).
Thus, routine replacement of CVCs is not necessary for cath-
eters that are functioning and have no evidence of causing
local or systemic complications.
Catheter replacement over a guidewire has become an
accepted technique for replacing a malfunctioning catheter or
exchanging a pulmonary artery catheter for a CVC when
invasive monitoring no longer is needed. Catheter insertion
over a guidewire is associated with less discomfort and a sig-
nificantly lower rate of mechanical complications than are those
percutaneously inserted at a new site (135); in addition, this
technique provides a means of preserving limited venous
access in some patients. Replacement of temporary catheters
over a guidewire in the presence of bacteremia is not an
acceptable replacement strategy, because the source of infec-
tion is usually colonization of the skin tract from the insertion
site to the vein (22,135). However, in selected patients with
tunneled hemodialysis catheters and bacteremia, catheter
exchange over a guidewire, in combination with antibiotic
therapy, might be an alternative as a salvage strategy in pa-
tients with limited venous access (136–139).
Hemodialysis Catheters
The use of catheters for hemodialysis is the most common
factor contributing to bacteremia in dialysis patients (140,141).
The relative risk for bacteremia in patients with dialysis cath-
eters is sevenfold the risk for patients with primary arterio-
venous fistulas (142). Despite the National Kidney
Foundation’s effort to reduce the number of hemodialysis
patients maintained with catheter access, catheter use increased
from 12.7% in 1995 to 22.2% in 1999 (143). Rates for bac-
teremia per 100 patient months were 0.2 for arteriovenous
fistulas, 0.5 for grafts, 5.0 for cuffed catheters, and 8.5 for
noncuffed catheters (CDC, unpublished data, 1999).
To reduce the rate of infection, hemodialysis catheters should
be avoided in favor of arteriovenous fistulas and grafts. If tem-
porary access is needed for dialysis, a cuffed catheter is prefer-
able to a noncuffed catheter, even in the ICU setting, if the
catheter is expected to stay in place for >3 weeks (11,144).
Pulmonary Artery Catheters
Pulmonary artery catheters are inserted through a Teflon®
introducer and typically remain in place an average of 3 days.
The majority of pulmonary artery catheters are heparin bonded,
which reduces not only catheter thrombosis but also micro-
bial adherence to the catheter (145). Meta-analysis indicates
that standard nonheparin-bonded pulmonary artery catheter
rates of CRBSI are 5.5 per 1,000 catheter days; for heparin-
bonded pulmonary artery catheters, this rate is 2.6 per 1,000
catheter days (11). Because the majority of pulmonary artery
catheters are heparin-bonded, the relative risk of infection with
these catheters is similar to that of CVC (2.6 versus 2.3 per
1,000 catheter days) (11).
A prospective study of 442 pulmonary artery catheters dem-
onstrated an increased risk for CRBSI after 5 days (0/442
CRBSI before 5 days versus 5/442 CSBSI after 5 days;
p < 0.001) (146). A prospective observational study of 71 pul-
monary artery catheters demonstrated higher infection rates
in catheters left in place longer than 7 days (2% before 7 days
versus 16% after 7 days; p = 0.056) (147). However, no stud-
ies indicate that catheter replacement at scheduled time inter-
vals is an effective method to reduce CRBSI (132,135). In
patients who continue to require hemodynamic monitoring,
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pulmonary artery catheters do not need to be changed more
frequently than every 7 days. No specific recommendation
can be made regarding routine replacement of catheters that
need to be in place for >7 days.
Pulmonary artery catheters are usually packaged with a thin
plastic sleeve that prevents touch contamination when placed
over the catheter. In a study of 166 catheters, patients who
were randomly assigned to have their catheters self-contained
within this sleeve had a reduced risk for CRBSI compared
with those who had a pulmonary artery catheter placed with-
out the sleeve (p = 0.002) (148).
Peripheral Arterial Catheters
Peripheral arterial catheters are usually inserted into the
radial or femoral artery and permit continuous blood pressure
monitoring and blood gas measurements. The rate of CRBSI
is comparable to that of temporary CVCs (2.9 versus 2.3 per
1,000 catheter days) (11). One study of peripheral arterial cath-
eters demonstrated no difference in infection rates between
changing catheters at scheduled times and changing arterial
catheters on an as-needed basis (132). One observational study
of 71 arterial catheters revealed that 10 local infections and
four CRBSIs occurred in patients who had peripheral arterial
catheters in place for >4 days compared with one local infec-
tion and no CRBSIs in patients whose catheters were in place
<4 days (p < 0.05) (147). Because the risk for CRBSI is likely
similar to that of short-term CVCs, arterial catheters can be
approached in a similar way. No specific recommendation can
be made regarding replacement of catheters that need to be in
place for >5 days.
Replacement of Administration Sets
The optimal interval for routine replacement of IV admin-
istration sets has been examined in three well-controlled
studies. Data from each of these studies reveal that replacing
administration sets no more frequently than 72 hours after
initiation of use is safe and cost-effective (149–151). Data
from a more recent study demonstrated that rates of phlebitis
were not substantially different if administration sets were left
in place 96 hours compared with 72 hours (128). When a
fluid that enhances microbial growth is infused (e.g., lipid
emulsions and blood products), more frequent changes of
administration sets are indicated, because these products have
been identified as independent risk factors for CRBSI (152–158).
Stopcocks (used for injection of medications, administra-
tion of IV infusions, and collection of blood samples) repre-
sent a potential portal of entry for microorganisms into vascular
access catheters and IV fluids. Stopcock contamination is com-
mon, occurring in 45% and 50% in the majority of series.
Whether such contamination is a substantial entry point of
CRBSI has been difficult to prove.
“Piggyback” systems are used as an alternative to stopcocks.
However, they also pose a risk for contamination of the intra-
vascular fluid if the device entering the rubber membrane of
an injection port is exposed to air or comes into direct contact
with nonsterile tape used to fix the needle to the port. Modi-
fied piggyback systems have the potential to prevent contami-
nation at these sites (159).
Needleless Intravascular Catheter
Systems
Attempts to reduce the incidence of sharp injuries and the
resultant risk for transmission of bloodborne infections to
health-care workers have led to the design and introduction
of needleless infusion systems. When the devices are used
according to manufacturers’ recommendations, they do not
substantially affect the incidence of CRBSI (160–167).
Multidose Parenteral Medication Vials
Parenteral medications commonly are dispensed in
multidose, parenteral medication vials that might be used for
prolonged periods for one or more patients. Although the over-
all risk for extrinsic contamination of multidose vials is likely
minimal (168), the consequences of contamination might
result in life-threatening infection (169,170). Single-use vials
are frequently preservative-free and might pose a risk for
contamination if they are punctured several times.
Special Considerations
for Intravascular Catheter-Related
Infections in Pediatric Patients
Prevention of CRBSI in children requires additional con-
siderations, although only certain studies have been performed
specifically in children. Pediatric data have been derived largely
from studies in neonatal or pediatric ICUs and pediatric on-
cology patients.
Epidemiology
As in adults, the majority of BSIs in children are associated
with the use of an intravascular catheter. From 1995 through
2000, the pooled mean catheter-associated BSI rate for all
pediatric ICUs reporting data to NNIS was 7.7 per 1,000 cath-
eter days (171,172). Umbilical catheter and CVC-associated
BSI rates for neonatal ICUs ranged from 11.3 per 1,000 cath-
eter days in children with birth weight <1,000 g to 4.0 per
1,000 catheter days in children whose birth weight was
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>2,500 g (171). Catheter utilization rates were comparable in
adult and pediatric ICUs (172,173).
Microbiology
As in adults, the majority of CRBSIs in children are caused
by coagulase-negative staphylococci. During 1992–1999, these
bacteria accounted for 37.7% of BSIs in pediatric
ICUs reporting to NNIS (12). Exposure to lipids has been
identified as an independent risk factor for development of
coagulase-negative staphylococcal bacteremia in very low birth
weight infants (i.e., those weighing <1,000 g) (odds ratio [OR]
= 9.4; 95% CI = 1.2–74.2) (155), as well as candidemia in the
neonatal ICU (OR = 5.33; 95% CI = 1.23–48.4) (154). Gram-
negative bacteria accounted for 25% of BSIs reported in pedi-
atric ICUs (172), whereas enterococci and Candida spp.
accounted for 10% and 9%, respectively (172).
Peripheral Venous Catheters
As in adults, the use of peripheral venous catheters in pedi-
atric patients might be complicated by phlebitis, infusion
extravasation, and catheter infection (174). Catheter location,
infusion of parenteral nutritional fluids with continuous IV
lipid emulsions, and length of ICU stay before catheter inser-
tion have all increased pediatric patients’ risk for phlebitis.
However, contrary to the risk in adults, the risk for phlebitis
in children has not increased with the duration of catheteriza-
tion (174,175).
Peripheral Arterial Catheters
In a prospective study of 340 peripheral arterial catheters in
children, the following two risk factors for catheter-related
infection were identified: 1) use of an arterial system that
permitted backflow of blood into the pressure tubing and
2) duration of catheterization (176). Although a correlation
was found between duration of arterial catheterization and
risk for catheter colonization, the risk remained constant for
2–20 days at 6.2% (176).
Umbilical Catheters
Although the umbilical stump becomes heavily colonized
soon after birth, umbilical-vessel catheterization often is used
for vascular access in newborn infants. Umbilical vessels can
be cannulated easily and permit both collection of blood
samples and measurement of hemodynamic status. The inci-
dences of catheter colonization and BSI are similar for
umbilical vein catheters and umbilical artery catheters. In sev-
eral studies, an estimated 40%–55% of umbilical artery cath-
eters were colonized and 5% resulted in CRBSI; umbilical
vein catheters were associated with colonization in 22%–59%
of cases (177–179) and with CRBSI in 3%–8% of cases (178).
Although CRBSI rates are similar for umbilical catheters in
the high position (i.e., above the diaphragm) compared with
the low position (i.e., below the diaphragm and above the aor-
tic bifurcation), catheters placed in the high position result in
a lower incidence of vascular complications without an
increase in adverse sequelae (178).
Risk factors for infection differ for umbilical artery and
umbilical vein catheters. In one study, neonates with very low
birth weight who also received antibiotics for >10 days were
at increased risk for umbilical artery CRBSIs (178). In com-
parison, those with higher birth weight and receipt of parenteral
nutrition fluids were at increased risk for umbilical vein CRBSI.
Duration of catheterization was not an independent risk fac-
tor for infection of either type of umbilical catheter.
CVCs
Because of the limited vascular sites in children, attention
should be given to the frequency with which catheters are
replaced in these patients. In a study in which survival analy-
sis techniques were used to examine the relation between the
duration of central venous catheterization and complications
in pediatric ICU patients, all of the patients studied (n = 397)
remained uninfected for a median of 23.7 days (180). In
addition, no relation was found between duration of catheter-
ization and the daily probability of infection (r = 0.21;
p > 0.1), suggesting that routine replacement of CVCs likely
does not reduce the incidence of catheter-related infection
(180).
Catheter Site Care
Although data regarding the use of the chlorhexidine-
impregnated sponge (Biopatch™) in children are limited, one
randomized, controlled study involving 705 neonates
reported a substantial decrease in colonized catheter tips in
infants in the Biopatch™ group compared with the group that
had standard dressings (15% versus 24%; RR = 0.6; 95%
CI = 0.5–0.9), but no difference in the rates of CRBSI or BSI
without a source. Biopatch™ was associated with localized
contact dermatitis in infants of very low birth weight. Of 98
neonates with very low birth weight, 15 (15%) developed
localized contact dermatitis; four (1.5%) of 237 neonates
weighing >1,000 g developed this reaction (p < 0.0001).
Infants with gestational age <26 weeks who had CVCs placed
at age <8 days were at increased risk for having localized con-
tact dermatitis, whereas no infants in the control group devel-
oped this local reaction (181).
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Performance Indicators
Performance indicators for reducing CRBSI are 1) imple-
mentation of educational programs that include didactic and
interactive components for those who insert and maintain
catheters; 2) use of maximal sterile barrier precautions during
catheter placement; 3) use of chlorhexidine for skin antisep-
sis; and 4) rates of catheter discontinuation when the catheter
is no longer essential for medical management. The impact
these recommendations will have on individual institutions
should be evaluated using specific performance indicators.
Recommendations for Placement
of Intravascular Catheters
in Adults and Children
These recommendations are designed to reduce the infec-
tious complications associated with intravascular catheter use.
Recommendations should be considered in the context of the
institution’s experience with catheter-related infections, expe-
rience with other adverse catheter-related complications (e.g.,
thrombosis, hemorrhage, and pneumothorax), and availabil-
ity of personnel skilled in the placement of intravascular
devices. Recommendations are provided for 1) intravascular-
catheter use in general; 2) specific devices; and 3) special cir-
cumstances (i.e., intravascular-device use in pediatric patients
and CVC use for parenteral nutrition and hemodialysis
access). Recommendations regarding the frequency of replac-
ing catheters, dressings, administration sets, and fluids also
are provided (Appendix B).
As in previous guidelines issued by CDC and HICPAC,
each recommendation is categorized on the basis of existing
scientific data, theoretical rationale, applicability, and economic
impact. The CDC/HICPAC system for categorizing recom-
mendations is as follows:
Category IA. Strongly recommended for implementation
and strongly supported by well-designed experimental, clini-
cal, or epidemiologic studies.
Category IB. Strongly recommended for implementation
and supported by some experimental, clinical, or epidemio-
logic studies, and a strong theoretical rationale.
Category IC. Required by state or federal regulations, rules,
or standards.
Category II. Suggested for implementation and supported
by suggestive clinical or epidemiologic studies or a theoretical
rationale.
Unresolved issue. Represents an unresolved issue for which
evidence is insufficient or no consensus regarding efficacy
exists.
I. Health-care worker education and training
A. Educate health-care workers regarding the indica-
tions for intravascular catheter use, proper proce-
dures for the insertion and maintenance of
intravascular catheters, and appropriate infection-
control measures to prevent intravascular catheter-
related infections (39,43,45–47,182–187).
Category IA
B. Assess knowledge of and adherence to guidelines
periodically for all persons who insert and manage
intravascular catheters (39,43,46,182,188).
Category IA
C. Ensure appropriate nursing staff levels in ICUs to
minimize the incidence of CRBSIs (48,189,190).
Category IB
II. Surveillance
A. Monitor the catheter sites visually or by palpation
through the intact dressing on a regular basis,
depending on the clinical situation of individual
patients. If patients have tenderness at the insertion
site, fever without obvious source, or other mani-
festations suggesting local or BSI, the dressing should
be removed to allow thorough examination of the
site (1,191–193). Category IB
B. Encourage patients to report to their health-care pro-
vider any changes in their catheter site or any new
discomfort. Category II
C. Record the operator, date, and time of catheter
insertion and removal, and dressing changes on a
standardized form. Category II
D. Do not routinely culture catheter tips (8,194,195).
Category IA
III. Hand hygiene
A. Observe proper hand-hygiene procedures either by
washing hands with conventional antiseptic-
containing soap and water or with waterless
alcohol-based gels or foams. Observe hand hygiene
before and after palpating catheter insertion sites, as
well as before and after inserting, replacing, access-
ing, repairing, or dressing an intravascular catheter.
Palpation of the insertion site should not be per-
formed after the application of antiseptic, unless
aseptic technique is maintained (43,70,196–200).
Category IA
B. Use of gloves does not obviate the need for hand
hygiene (43,198,199). Category IA
IV. Aseptic technique during catheter insertion and care
A. Maintain aseptic technique for the insertion and care of
intravascular catheters (22,71,201,202). Category IA
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B. Wear clean or sterile gloves when inserting an intra-
vascular catheter as required by the Occupational
Safety and Health Administration Bloodborne
Pathogens Standard. Category IC. Wearing clean
gloves rather than sterile gloves is acceptable for the
insertion of peripheral intravascular catheters if the
access site is not touched after the application of
skin antiseptics. Sterile gloves should be worn for
the insertion of arterial and central catheters
(201,203). Category IA
C. Wear clean or sterile gloves when changing the dress-
ing on intravascular catheters. Category IC
V. Catheter insertion
Do not routinely use arterial or venous cutdown
procedures as a method to insert catheters (204–206).
Category IA
VI. Catheter site care
A. Cutaneous antisepsis
1. Disinfect clean skin with an appropriate anti-
septic before catheter insertion and during dress-
ing changes. Although a 2% chlorhexidine-
based preparation is preferred, tincture of
iodine, an iodophor, or 70% alcohol can be used
(73,75,207,208). Category IA
2. No recommendation can be made for the use
of chlorhexidine in infants aged <2 months.
Unresolved issue
3. Allow the antiseptic to remain on the insertion
site and to air dry before catheter insertion.
Allow povidone iodine to remain on the skin
for at least 2 minutes, or longer if it is not yet dry
before insertion (73,75,207,208). Category IB
4. Do not apply organic solvents (e.g., acetone and
ether) to the skin before insertion of catheters
or during dressing changes (209). Category IA
VII. Catheter-site dressing regimens
A. Use either sterile gauze or sterile, transparent, semi-
permeable dressing to cover the catheter site
(146,210–212). Category IA
B. Tunneled CVC sites that are well healed might not
require dressings. Category II
C. If the patient is diaphoretic, or if the site is bleeding
or oozing, a gauze dressing is preferable to a trans-
parent, semi-permeable dressing (146,210–212).
Category II
D. Replace catheter-site dressing if the dressing becomes
damp, loosened, or visibly soiled (146,210).
Category IB
E. Change dressings at least weekly for adult and ado-
lescent patients depending on the circumstances of
the individual patient (211). Category II
F. Do not use topical antibiotic ointment or creams
on insertion sites (except when using dialysis cath-
eters) because of their potential to promote fungal
infections and antimicrobial resistance (107,213).
Category IA (See Central Venous Catheters, Includ-
ing PICCs, Hemodialysis, and Pulmonary Artery
Catheters, in Adult and Pediatric Patients, Section
II.I.)
G. Do not submerge the catheter under water. Show-
ering should be permitted if precautions can be taken
to reduce the likelihood of introducing organisms
into the catheter (e.g., if the catheter and connect-
ing device are protected with an impermeable cover
during the shower (214,215). Category II
VIII. Selection and replacement of intravascular catheters
A. Select the catheter, insertion technique, and inser-
tion site with the lowest risk for complications
(infectious and noninfectious) for the anticipated
type and duration of IV therapy (22,55,59,
216–218). Category IA
B. Promptly remove any intravascular catheter that is
no longer essential (219,220). Category IA
C. Do not routinely replace central venous or arterial
catheters solely for the purposes of reducing the
incidence of infection (134,135,221). Category IB
D. Replace peripheral venous catheters at least every
72–96 hours in adults to prevent phlebitis (128).
Leave peripheral venous catheters in place in chil-
dren until IV therapy is completed, unless compli-
cations (e.g., phlebitis and infiltration) occur
(174,175,222,223). Category IB
E. When adherence to aseptic technique cannot be
ensured (i.e., when catheters are inserted during a
medical emergency), replace all catheters as soon as
possible and after no longer than 48 hours
(22,71,201,202). Category II
F. Use clinical judgment to determine when to replace
a catheter that could be a source of infection (e.g.,
do not routinely replace catheters in patients whose
only indication of infection is fever). Do not rou-
tinely replace venous catheters in patients who are
bacteremic or fungemic if the source of infection is
unlikely to be the catheter (224). Category II
G. Replace any short-term CVC if purulence is
observed at the insertion site, which indicates
infection (224,225). Category IB
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H. Replace all CVCs if the patient is hemodynamically
unstable and CRBSI is suspected (224,225).
Category II
I. Do not use guidewire techniques to replace cath-
eters in patients suspected of having catheter-related
infection (134,135). Category IB
IX. Replacement of administration sets*, needleless systems,
and parenteral fluids
A. Administration sets
1. Replace administration sets, including second-
ary sets and add-on devices, no more frequently
than at 72-hour intervals, unless catheter-related
infection is suspected or documented (23,
149–151). Category IA
2. Replace tubing used to administer blood, blood
products, or lipid emulsions (those combined
with amino acids and glucose in a 3-in-1
admixture or infused separately) within 24 hours
of initiating the infusion (158,226–229).
Category IB. If the solution contains only dex-
trose and amino acids, the administration set
does not need to be replaced more frequently
than every 72 hours (226). Category II
3. Replace tubing used to administer propofol
infusions every 6 or 12 hours, depending on its
use, per the manufacturer’s recommendation
(230). Category IA
B. Needleless intravascular devices
1. Change the needleless components at least as
frequently as the administration set (160–162,
164–167). Category II
2. Change caps no more frequently than every 72
hours or according to manufacturers’ recom-
mendations (160,162,165,166). Category II
3. Ensure that all components of the system are
compatible to minimize leaks and breaks in the
system (163). Category II
4. Minimize contamination risk by wiping the
access port with an appropriate antiseptic and
accessing the port only with sterile devices
(162,163,165). Category IB
C. Parenteral fluids
1. Complete the infusion of lipid-containing
solutions (e.g., 3-in-1 solutions) within 24 hours
of hanging the solution (156–158,226,229).
Category IB
2. Complete the infusion of lipid emulsions alone
within 12 hours of hanging the emulsion. If
volume considerations require more time, the
infusion should be completed within 24 hours
(156–158). Category IB
3. Complete infusions of blood or other blood
products within 4 hours of hanging the blood
(231–234). Category II
4. No recommendation can be made for the hang
time of other parenteral fluids. Unresolved issue
X. IV-injection ports
A. Clean injection ports with 70% alcohol or an
iodophor before accessing the system (164,235,236).
Category IA
B. Cap all stopcocks when not in use (235). Category IB
XI. Preparation and quality control of IV admixtures
A. Admix all routine parenteral fluids in the pharmacy
in a laminar-flow hood using aseptic technique
(237,238). Category IB
B. Do not use any container of parenteral fluid that
has visible turbidity, leaks, cracks, or particulate
matter or if the manufacturer’s expiration date has
passed (237). Category IB
C. Use single-dose vials for parenteral additives or medi-
cations when possible (237,239). Category II
D. Do not combine the leftover content of single-use
vials for later use (237,239). Category IA
E. If multidose vials are used
1. Refrigerate multidose vials after they are opened
if recommended by the manufacturer.
Category II
2. Cleanse the access diaphragm of multidose
vials with 70% alcohol before inserting a
device into the vial (236). Category IA
3. Use a sterile device to access a multidose vial
and avoid touch contamination of the device
before penetrating the access diaphragm
(235,240). Category IA
4. Discard multidose vial if sterility is compro-
mised (235,240). Category IA
XII. In-line filters
Do not use filters routinely for infection-control pur-
poses (80,241). Category IA
XIII. IV-therapy personnel
Designate trained personnel for the insertion and
maintenance of intravascular catheters (46,47,210,242).
Category IA
* Administration sets include the area from the spike of tubing entering the fluid
container to the hub of the vascular access device. However, a short extension
tube might be connected to the catheter and might be considered a portion of
the catheter to facilitate aseptic technique when changing administration sets.
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XIV. Prophylactic antimicrobials
Do not administer intranasal or systemic antimicro-
bial prophylaxis routinely before insertion or during use
of an intravascular catheter to prevent catheter coloni-
zation or BSI (97,98,108,243). Category IA
Peripheral Venous Catheters, Including
Midline Catheters, in Adult
and Pediatric Patients
 I. Selection of peripheral catheter
A. Select catheters on the basis of the intended purpose
and duration of use, known complications (e.g., phle-
bitis and infiltration), and experience of individual
catheter operators (67,68,244). Category IB
B. Avoid the use of steel needles for the administration
of fluids and medication that might cause tissue
necrosis if extravasation occurs (67,68). Category IA
C. Use a midline catheter or PICC when the duration of
IV therapy will likely exceed 6 days (244). Category IB
II. Selection of peripheral-catheter insertion site
A. In adults, use an upper- instead of a lower-extremity
site for catheter insertion. Replace a catheter inserted
in a lower-extremity site to an upper-extremity site as
soon as possible (67,245). Category IA
B. In pediatric patients, the hand, the dorsum of the
foot, or the scalp can be used as the catheter insertion
site. Category II
C. Replacement of catheter
1. Evaluate the catheter insertion site daily, by pal-
pation through the dressing to discern tenderness
and by inspection if a transparent dressing is in
use. Gauze and opaque dressings should not be
removed if the patient has no clinical signs infec-
tion. If the patient has local tenderness or other
signs of possible CRBSI, an opaque dressing
should be removed and the site inspected visu-
ally. Category II
2. Remove peripheral venous catheters if the patient
develops signs of phlebitis (e.g., warmth, tender-
ness, erythema, and palpable venous cord),
infection, or a malfunctioning catheter (66).
Category IB
3. In adults, replace short, peripheral venous cath-
eters at least 72–96 hours to reduce the risk for
phlebitis. If sites for venous access are limited and
no evidence of phlebitis or infection is present,
peripheral venous catheters can be left in place
for longer periods, although the patient and the
insertion sites should be closely monitored
(66,128,246). Category IB
4. Do not routinely replace midline catheters to
reduce the risk for infection (131). Category IB
5. In pediatric patients, leave peripheral venous cath-
eters in place until IV therapy is completed,
unless a complication (e.g., phlebitis and infil-
tration) occurs (174,175,222,223). Category IB
 III. Catheter and catheter-site care
Do not routinely apply prophylactic topical antimi-
crobial or antiseptic ointment or cream to the insertion
site of peripheral venous catheters (107,213). Category
IA
Central Venous Catheters, Including
PICCs, Hemodialysis, and Pulmonary
Artery Catheters, in Adult
and Pediatric Patients
I. Surveillance
A. Conduct surveillance in ICUs and other patient popu-
lations to determine CRBSI rates, monitor trends in
those rates, and assist in identifying lapses in infection-
control practices (3,12,16,247–250). Category IA
B. Express ICU data as the number of catheter-associated
BSIs per 1,000 catheter-days for both adults and chil-
dren and stratify by birth weight categories for neo-
natal ICUs to facilitate comparisons with national data
in comparable patient populations and health-care
settings (3,12,16,247–250). Category IB
C. Investigate events leading to unexpected life-threatening
or fatal outcomes. This includes any process varia-
tion for which a recurrence would likely present an
adverse outcome (13). Category IC
II. General principles
A. Use a CVC with the minimum number of ports or
lumens essential for the management of the patient
(251–254). Category IB
B. Use an antimicrobial or antiseptic-impregnated CVC
in adults whose catheter is expected to remain in place
>5 days if, after implementing a comprehensive strat-
egy to reduce rates of CRBSI, the CRBSI rate remains
above the goal set by the individual institution based
on benchmark rates (Table 2) and local factors. The
comprehensive strategy should include the following
three components: educating persons who insert and
maintain catheters, use of maximal sterile barrier
precautions, and a 2% chlorhexidine preparation
for skin antisepsis during CVC insertion
(84–86,90,91,255). Category IB
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C. No recommendation can be made for the use of
impregnated catheters in children. Unresolved issue
D. Designate personnel who have been trained and
exhibit competency in the insertion of catheters to
supervise trainees who perform catheter insertion
(39,43,46,182,187,188). Category IA
E. Use totally implantable access devices for patients who
require long-term, intermittent vascular access. For
patients requiring frequent or continuous access, a
PICC or tunneled CVC is preferable (256,257).
Category II
F. Use a cuffed CVC for dialysis if the period of tempo-
rary access is anticipated to be prolonged (e.g., >3
weeks) (144,258). Category IB
G. Use a fistula or graft instead of a CVC for permanent
access for dialysis (142). Category IB
H. Do not use hemodialysis catheters for blood drawing
or applications other than hemodialysis except dur-
ing dialysis or under emergency circumstances.
Category II
I. Use povidone-iodine antiseptic ointment at the
hemodialysis catheter exit site after catheter insertion
and at the end of each dialysis session only if this
ointment does not interact with the material of the
hemodialysis catheter per manufacturer’s recommen-
dation (103,114,144). Category II
III. Selection of catheter insertion site
A. Weigh the risk and benefits of placing a device at a
recommended site to reduce infectious complications
against the risk for mechanical complications (e.g.,
pneumothorax, subclavian artery puncture, subclavian
vein laceration, subclavian vein stenosis, hemotho-
rax, thrombosis, air embolism, and catheter misplace-
ment) (22,55,59,218). Category IA
B. Use a subclavian site (rather than a jugular or a femo-
ral site) in adult patients to minimize infection risk
for nontunneled CVC placement (22,55,59,60).
Category IA
C. No recommendation can be made for a preferred
site of insertion to minimize infection risk for a
nontunneled CVC (61–63). Unresolved issue
D. Place catheters used for hemodialysis and pheresis in
a jugular or femoral vein rather than a subclavian vein
to avoid venous stenosis if catheter access is needed
(259–263). Category IA
IV. Maximal sterile barrier precautions during catheter
insertion
A. Use aseptic technique including the use of a cap, mask,
sterile gown, sterile gloves, and a large sterile sheet,
for the insertion of CVCs (including PICCS) or
guidewire exchange (22,71). Category IA
B. Use a sterile sleeve to protect pulmonary artery cath-
eters during insertion (148). Category IB
V. Replacement of catheter
A. Do not routinely replace CVCs, PICCs, hemodialy-
sis catheters, or pulmonary artery catheters to pre-
vent catheter-related infections (132,134,135).
Category IB
B. Do not remove CVCs or PICCs on the basis of fever
alone. Use clinical judgment regarding the appropri-
ateness of removing the catheter if infection is evi-
denced elsewhere or if a noninfectious cause of fever
is suspected (224,264). Category II
C. Guidewire exchange
1. Do not use guidewire exchanges routinely for
nontunneled catheters to prevent infection
(135,265). Category IB
2. Use a guidewire exchange to replace a malfunc-
tioning nontunneled catheter if no evidence of
infection is present (135,265). Category IB
3. Use a new set of sterile gloves before handling
the new catheter when guidewire exchanges are
performed (22,71). Category II
 VI. Catheter and catheter-site care
A. General measures
Designate one port exclusively for hyperalimen-
tation if a multilumen catheter is used to administer
parenteral nutrition (266). Category II
B. Antibiotic lock solutions
Do not routinely use antibiotic lock solutions to
prevent CRBSI. Use prophylactic antibiotic lock
solution only in special circumstances (e.g., in treat-
ing a patient with a long-term cuffed or tunneled cath-
eter or port who has a history of multiple CRBSIs
despite optimal maximal adherence to aseptic tech-
nique) (115,116,267,268). Category II
C. Catheter-site dressing regimens
1. Replace the catheter-site dressing when it becomes
damp, loosened, or soiled or when inspection of
the site is necessary (65,146,211). Category IA
2. Replace dressings used on short-term CVC sites
every 2 days for gauze dressings and at least every
7 days for transparent dressings, except in those
pediatric patients in which the risk for dis-
lodging the catheter outweighs the benefit of
changing the dressing (211). Category IB
3. Replace dressings used on tunneled or implanted
CVC sites no more than once per week, until the
insertion site has healed (211). Category IB
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4. No recommendation can be made regarding the
necessity for any dressing on well-healed exit sites
of long-term cuffed and tunneled CVCs.
Unresolved issue
D. No recommendation can be made for the use of
chlorhexidine sponge dressings to reduce the incidence
of infection. Unresolved issue
E. Do not use chlorhexidine sponge dressings in neo-
nates aged <7 days or of gestational age <26 weeks
(181). Category II
F. No recommendation can be made for the use of
sutureless securement devices. Unresolved issue
G. Ensure that catheter-site care is compatible with the
catheter material (109,110). Category IB
H. Use a sterile sleeve for all pulmonary artery catheters
(148). Category IB
Additional Recommendations
for Peripheral Arterial Catheters
and Pressure Monitoring Devices
for Adult and Pediatric Patients
 I. Selection of pressure monitoring system
Use disposable, rather than reusable, transducer assem-
blies when possible (269–273). Category IB
II. Replacement of catheter and pressure monitoring system
A. Do not routinely replace peripheral arterial catheters
to prevent catheter-related infections (132,147,
221,274). Category II
B. Replace disposable or reusable transducers at 96-hour
intervals. Replace other components of the system
(including the tubing, continuous-flush device, and
flush solution) at the time the transducer is replaced
(22,270). Category IB
III. Care of pressure monitoring systems
A. General measures
1. Keep all components of the pressure monitoring
system (including calibration devices and flush
solution) sterile (269,275–277). Category IA
2. Minimize the number of manipulations of and
entries into the pressure monitoring system. Use
a closed-flush system (i.e., continuous flush),
rather than an open system (i.e., one that requires
a syringe and stopcock), to maintain the patency
of the pressure monitoring catheters (272,278).
Category II
3. When the pressure monitoring system is accessed
through a diaphragm rather than a stopcock, wipe
the diaphragm with an appropriate antiseptic
before accessing the system (272). Category IA
4. Do not administer dextrose-containing solutions
or parenteral nutrition fluids through the pressure
monitoring circuit (272,279,280). Category IA
B. Sterilization or disinfection of pressure monitoring
systems
1. Use disposable transducers (272,279–282).
Category IB
2. Sterilize reusable transducers according to the
manufacturers’ instructions if the use of dispos-
able transducers is not feasible (272,279–282).
Category IA
Recommendations for Umbilical
Catheters
I. Replacement of catheters
A. Remove and do not replace umbilical artery catheters
if any signs of CRBSI, vascular insufficiency, or throm-
bosis are present (283). Category II
B. Remove and do not replace umbilical venous cath-
eters if any signs of CRBSI or thrombosis are present
(283). Category II
C. No recommendation can be made for treating through
an umbilical venous catheter suspected of being
infected. Unresolved issue
D. Replace umbilical venous catheters only if the cath-
eter malfunctions. Category II
II. Catheter-site care
A. Cleanse the umbilical insertion site with an antisep-
tic before catheter insertion. Avoid tincture of iodine
because of the potential effect on the neonatal
thyroid. Other iodine-containing products (e.g.,
povidone-iodine) can be used (75,177,178,284,285).
Category IB
B. Do not use topical antibiotic ointment or creams on
umbilical catheter insertion sites because of the
potential to promote fungal infections and antimi-
crobial resistance (107,213). Category IA
C. Add low doses of heparin (0.25–1.0 F/ml) to the fluid
infused through umbilical arterial catheters
(286–288). Category IB
D. Remove umbilical catheters as soon as possible when
no longer needed or when any sign of vascular insuf-
ficiency to the lower extremities is observed. Opti-
mally, umbilical artery catheters should not be left in
place >5 days (283,289). Category II
E. Umbilical venous catheters should be removed as soon
as possible when no longer needed but can be used
up to 14 days if managed aseptically (290,291).
Category II
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Appendix A
Examples of Clinical Definitions
for Catheter-Related Infections
Localized Catheter Colonization
Significant growth of a microorganism (>15 CFU) from the cath-
eter tip, subcutaneous segment of the catheter, or catheter hub
Exit Site Infection
Erythema or induration within 2 cm of the catheter exit
site, in the absence of concomitant bloodstream infection (BSI)
and without concomitant purulence
Clinical Exit Site Infection (Or Tunnel
Infection)
Tenderness, erythema, or site induration >2 cm from the
catheter site along the subcutaneous tract of a tunneled (e.g.,
Hickman or Broviac) catheter, in the absence of concomitant
BSI
Pocket Infection
Purulent fluid in the subcutaneous pocket of a totally
implanted intravascular catheter that might or might not be
associated with spontaneous rupture and drainage or necrosis
of the overlaying skin, in the absence of concomitant BSI
Infusate-Related BSI
Concordant growth of the same organism from the infusate
and blood cultures (preferably percutaneously drawn) with no
other identifiable source of infection
Catheter-Related BSI
Bacteremia/fungemia in a patient with an intravascular cath-
eter with at least one positive blood culture obtained from a
peripheral vein, clinical manifestations of infections (i.e.,
fever, chills, and/or hypotension), and no apparent source for
the BSI except the catheter. One of the following should be
present: a positive semiquantitative (>15 CFU/catheter seg-
ment) or quantitative (>103 CFU/catheter segment catheter)
culture whereby the same organism (species and antibiogram)
is isolated from the catheter segment and peripheral blood;
simultaneous quantitative blood cultures with a >5:1 ratio CVC
versus peripheral; differential period of CVC culture versus
peripheral blood culture positivity of >2 hours.
Surveillance Definitions for Primary
BSIs, National Nosocomial
Infections Surveillance System
Laboratory-Confirmed BSI
Should meet at least one of the following criteria:
Criterion 1: Patient has a recognized pathogen cultured from
one or more blood cultures, and the pathogen cultured from
the blood is not related to an infection at another site.
Criterion 2: Patient has at least one of the following signs or
symptoms: fever (>100.4º F [>38º C]), chills, or hypotension,
and at least one of the following:
1. Common skin contaminant (e.g., diphtheroids, Bacillus
spp., Propionibacterium spp., coagulase-negative
staphylococci, or micrococci) cultured from two or more
blood cultures drawn on separate occasions.
2. Common skin contaminant (e.g., diphtheroids, Bacillus
spp., Propionibacterium spp., coagulase-negative
staphylococci, or micrococci) cultured from at least one
blood culture from a patient with an intravenous line,
and the physician institutes appropriate antimicrobial
therapy.
3. Positive antigen test on blood (e.g., Hemophilus influenzae,
Streptococcus pneumoniae, Neisseria meningitides, or group
B streptococcus).
and signs and symptoms with positive laboratory results
are not related to an infection at another site.
Criterion 3: Patient aged <1 year has at least one of the fol-
lowing signs or symptoms: fever (>100.4º F [>38º C]), hypoth-
ermia (<98.6º F [<37º C]), apnea, or bradycardia, and at least
one of the following:
1. Common skin contaminant (e.g., diphtheroids, Bacillus
spp., Propionibacterium spp., coagulase-negative
staphylococci, or micrococci) cultured from two or more
blood cultures drawn on separate occasions.
2. Common skin contaminant (e.g., diphtheroids, Bacillus
spp., Propionibacterium spp., coagulase-negative
staphylococci, or micrococci) cultured from at least one
blood culture from a patient with an intravenous line, and
the physician institutes appropriate antimicrobial therapy.
3. Positive antigen test on blood (e.g., Hemophilus influenzae,
Streptococcus pneumoniae, Neisseria meningitides, or group
B streptococcus).
and signs and symptoms with positive laboratory results
are not related to an infection at another site.
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Clinical Sepsis
Should meet at least one of the following criteria:
Criterion 1: Patient has at least one of the following clinical
signs with no other recognized cause: fever (>100.4º F [>38º C]),
hypotension (systolic pressure <90 mm Hg), or oliguria
(<20 mL/hr), and blood culture not done or no organisms or
antigen detected in blood and no apparent infection at
another site, and physician institutes treatment for sepsis.
Criterion 2: Patient aged <1 year has at least one of the follow-
ing clinical signs or symptoms with no other recognized cause:
fever (>100.4º F [>38º C]), hypothermia (<98.6º F [<37º C]),
apnea, or bradycardia, and blood culture not done or no or-
ganisms or antigen detected in blood and no apparent infec-
tion at another site, and physician institutes treatment for
sepsis.
Catheter-Associated BSI
Defined by the following:
• Vascular access device that terminates at or close to the
heart or one of the great vessels. An umbilical artery or
vein catheter is considered a central line.
• BSI is considered to be associated with a central line if the
line was in use during the 48-hour period before develop-
ment of the BSI. If the time interval between onset of
infection and device use is >48 hours, there should be
compelling evidence that the infection is related to the
central line.
Arterial or Venous Infection
Included are arteriovenous graft, shunt, fistula, or intrave-
nous cannulation. Should meet at least one of the following
criteria:
Criterion 1: Patient has organisms cultured from arteries or
veins removed during a surgical operation and blood culture
not done or no organisms cultured from blood.
Criterion 2: Patient has evidence of arterial or venous infec-
tion seen during a surgical operation or histopathologic
examination.
Criterion 3: Patient has at least one of the following signs or
symptoms with no other recognized cause: fever (>100.4º F
[>38º C]), pain, erythema, or heat at involved vascular site and
>15 CFUs cultured from an intravascular cannula tip using a
semiquantitative culture method and blood culture not done
or no organisms cultured from blood.
Criterion 4: Patient has purulent drainage at the involved
vascular site and blood culture not done or no organisms cul-
tured from blood.
Criterion 5: Patient aged <1 year has at least one of the fol-
lowing signs or symptoms with no other recognized cause:
fever (>100.4º F [>38º C]), hypothermia (<98.6º F [<37º C]),
apnea, bradycardia, lethargy, or pain, erythema or heat at
involved vascular site and >15 colonies cultured from intra-
vascular cannula tip using semiquantitative method and blood
culture not done or no organisms cultured from blood.
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Appendix B
Summary of Recommended Frequency of Replacements for Catheters,
Dressings, Administration Sets, and Fluids
Peripheral venous
catheters
Midline catheters
Peripheral arterial
catheters
Central venous
catheters
including
peripherally
inserted central
catheters and
hemodialysis
catheters
Pulmonary artery
catheters
Umbilical
catheters
Replacement and relocation
of device
In adults, replace catheter
and rotate site no more
frequently than every
72–96 hours. Replace
catheters inserted under
emergency basis and insert
a new catheter at a different
site within 48 hours. In
pediatric patients, do not
replace peripheral catheters
unless clinically indicated.
No recommendation for the
frequency of the catheter
replacement.
In adults, do not replace
catheters routinely to
prevent catheter-related
infection. In pediatric
patients, no recommenda-
tion for the frequency of
catheter replacement.
Replace disposable or
reusable transducers at 72-
hour intervals. Replace
continuous flush device at
the time the transducer is
replaced.
Do not routinely replace
catheters.
Do not replace catheter to
prevent catheter-related
infection.
Do not routinely replace
catheters.
Replace dressing when the
catheter is removed or
replaced, or when the
dressing becomes damp,
loosened, or soiled. Replace
dressings more frequently in
diaphoretic patients. In
patients who have large
bulky dressings that prevent
palpation or direct
visualization of the catheter
insertion site, remove the
dressing and visually inspect
the catheter at least daily
and apply a new dressing.
As above.
Replace dressing when the
catheter is replaced, or when
the dressing becomes damp,
loosened, or soiled, or when
inspection of the site is
necessary.
Replace gauze dressings
every 2 days and transpar-
ent dressings every 7 days
on short-term catheters.
Replace the dressing when
the catheter is replaced, or
when the dressing becomes
damp, loosened, or soiled, or
when inspection of the site is
necessary.
As above.
Not applicable.
Replace intravenous tubing,
including add-on devices, no more
frequently than at 72-hour intervals
unless clinically indicated. Replace
tubing used to administer blood,
blood products, or lipid emulsions
within 24 hours of initiating the
infusion.
No recommendation for replacement
of tubing used for intermittent
infusions. Consider short extension
tubing connected to the catheter to
be a portion of the device. Replace
such extension tubing when the
catheter is changed.
As above.
Replace the intravenous tubing at the
time the transducer is replaced (i.e.,
72-hour intervals).
Replace intravenous tubing and add-
on devices no more frequently than
at 72-hour intervals. Replace tubing
used to administer blood products or
lipid emulsions within 24 hours of
initiating the infusion.
As above.
Replace intravenous tubing and add-
on devices no more frequently than
at 72-hour intervals. Replace tubing
used to administer blood products or
lipid emulsions within 24 hours of
initiating the infusion.
No recommendation for the hang time
of intravenous fluids, including
nonlipid-containing parenteral nutrition
fluids. Complete infusion of lipid-
containing parenteral nutrition fluids
(e.g., 3-in-1 solutions) within 24 hours
of hanging the fluid. Complete infusion
of lipid emulsions alone within 12
hours of hanging the fluid. Complete
infusions of blood products within 4
hours of hanging the product.
As above.
Replace the flush solution at the time
the transducer is replaced (i.e., 72-
hour intervals).
No recommendation for the hang time
of intravenous fluids, including
nonlipid-containing parenteral nutrition
fluids. Complete infusions of lipid-
containing fluids within 24 hours of
hanging the fluid.
As above.
No recommendation for the hang time
of intravenous fluids, including
nonlipid-containing parenteral nutrition
fluids. Complete infusion of lipid-
containing fluids within 24 hours of
hanging the fluid. Includes nontunneled
catheters, tunneled catheters, and
totally implanted devices.
Replacement and Replacement of Replacement of Hang time for
Catheter relocation of device catheter site dressing administration sets parenteral fluids
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